In the USA, average-risk patients account for approximately 75% of CRC and include persons older than 50 years with no other known risk factor, moderate-risk patients account for 15 - 20% of CRC and include those with a positive family history of colorectal adenomatous polyps or cancer and high-risk patients account for 5 - 15% of CRC and include those with FAP, hereditary non-polyposis colorectal cancer (HNPCC) or long-standing IBD. [58,59] Therefore, the majority of CRC are non-hereditary and sporadic, which makes early detection important. There is good evidence demonstrating reduced morbidity and mortality associated with early detection of invasive lesions and precursor adenomatous polyps. However, most CRC in the world is diagnosed at an advanced stage. Therefore, most attention has focused on screening for targets for cancer chemoprevention to reduce the number of CRC patients.